Johnson & Johnson (JNJ) Stock News

JNJ's board approved a $1.34 per share cash dividend for the fourth quarter, in line with the prior quarter's rate. The payment continues the company's long dividend history.

The orthopaedics segment generated $2.35 billion in Q3, part of the company's broader earnings release.

Johnson & Johnson posted $14.96 billion in U.S. sales for the third quarter.

Johnson & Johnson reported third-quarter net income of $210 million, according to a flash headline. Further details were not immediately available.

Phase 3 ICONIC-LEAD data at Fall Clinical Dermatology show >=72% of patients achieved PASI 90 and >=70% clear/almost clear skin at two years, with no new safety signals. 85% of responders regained response after retreatment.

J&J reports 50% of patients progression-free at five years without maintenance after single CARVYKTI infusion in early-line multiple myeloma. Five-year OS 69.2%, median PFS 60.5 months. Data from CARTITUDE-2 Cohort A (N=20) presented at IMS. No new neurotoxicity. Supports earlier use of CAR-T.

New Phase 3 model-based analysis from the MajesTEC-3 study projects 87% of patients treated with TECVAYLI plus DARZALEX FASPRO (Tec-Dara) as early as second line may have mortality risk comparable to the age-matched general population. Median overall survival was estimated at 18.5 years, nearly four-fold longer than the standard-of-care comparator. The survival benefit was driven by a 90% reduction in disease progression risk without a significant increase in non-relapse mortality. Data were presented at the IMS Annual Meeting. The EC approved the combination for relapsed/refractory Multiple Myeloma after at least one prior therapy in August 2026.

J&J Phase 3 MajesTEC-3: TECVAYLI Plus DARZALEX Sustains Control and Survival

A new model-based analysis from Johnson & Johnson suggests TECVAYLI plus DARZALEX FASPRO could improve long-term survival in patients with early-line relapsed/refractory multiple myeloma. The analysis adds to existing clinical data supporting the combination.

Johnson & Johnson (JNJ) stock has reportedly reached a new 52-week high today. The claim comes from an unverified source. No further details are available.